Systemic bevacizumab for recurrent respiratory papillomatosis. A case series

Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV) 6/11 related, predominantly histologically benign neoplasm of the upper and lower airway affecting both younger and older patients. Though potentially declining due to HPV vaccination RRP is still challenging in management and a significant cause of affected quality of life. Systemic bevacizumab has shown efficacy for aggressive disease in other case series in juvenile-onset RRP (JORRP) as in adult-onset RRP (AORRP). We present five consecutive patients with AORRP treated with systemic bevacizumab for aggressive laryngeal and tracheal papillomatosis. Adding to the findings of previous reports we show that systemic bevacizumab treatment could have positive influence on aggressive AORRP without pulmonary spread with manageable side effects.

Automated summary

Recurrent respiratory papillomatosis (RRP) is a neoplasm caused by human papilloma virus (HPV) 6/11, which affects the upper and lower airway in both younger and older patients. Despite the potential decline due to HPV vaccination, RRP remains challenging to manage and significantly impacts quality of life. Systemic bevacizumab has shown efficacy in treating aggressive RRP in both juvenile and adult patients. In this study, five consecutive adult patients with aggressive laryngeal and tracheal papillomatosis were treated with systemic bevacizumab, demonstrating positive effects without pulmonary spread and manageable side effects.